2281-PUB: Quality of Life in Japanese Patients with Type 2 Diabetes Mellitus
Authors: TAKAHASHI KENICHIRO , TERAUCHI YASUO , YAMAKAWA TADASHI 
Published: June 2020

Introduction: The ultimate goal of antihyperglycemic treatment for people with diabetes is to have a similar longevity and quality of life (QOL) as those without diabetes. No study has specifically aimed at assessing the association between glycemic control and QOL in general type 2 diabetes patients in Japan. We therefore wanted to evaluate QOL in Japanese type 2 diabetes (T2DM) patients using a validated diabetes treatment related-QOL (DTR-QOL) questionnaire. The aim of this study was to investigate the association between glycemic controls and QOL among Japanese patients with T2DM. We presented its interim report on 77th scientific session in June, 2017. We will finally submit our final report this time.
Methods: We conducted a large-scale multi-centered, cross-sectional study and analyzed a total of 3,259 type 2 diabetes patients who provided valid answers to the DTR-QOL questionnaire.
Results: Among 3,259 patients, 61% were male and 39% were female. The mean age was 63.0 ± 11.8 years, the mean BMI was 25.3 ± 4.8 kg/m2, and the mean HbA1c was 7.5 ± 1.6%. There was a significant negative correlation between the total DTR-QOL score and HbA1c (ρ =-0.325, p&lt;0.0001). The total DTR-QOL score increased with increasing age (p &lt; 0.0001) and decreased with increased BMI (p &lt; 0.0001) and increased HbA1c levels (p &lt; 0.0001). In multiple regression analysis, adjusted for age, sex and BMI, HbA1c (β=-0.229, p&lt;0.0001), neuropathy (β=0.082, p&lt;0.0001), macroangiopathy (β=0.050, p=0.0027), and insulin injection (β=0.196, p&lt;0.0001) were found to be independent factors with significant effects on DTR-QOL.
Conclusions: Our results show that poor blood glucose control, diabetic neuropathy, macroangiopathy, and insulin injections are factors that lead to reduced QOL in type 2 diabetes patients. In routine practice, healthcare professionals should not forget to evaluate the patient’s QOL in addition to assessing blood glucose control status and other factors.

Disclosure
K. Takahashi: None. Y. Terauchi: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Novo Nordisk A/S, Sanofi. Consultant; Self; Astellas Pharma Inc. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Ono Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited. Speaker’s Bureau; Self; Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Eli Lilly Japan K.K., Kowa Company, Ltd., Medscape, Medtronic, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Terumo Medical Corporation. T. Yamakawa: None.